Brokers Set Expectations for XENE FY2026 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer anticipates that the biopharmaceutical company will earn ($3.58) per share for the year. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.07. The firm had revenue of $7.50 million for the quarter, compared to the consensus estimate of $1.64 million. During the same period in the prior year, the business earned ($0.62) earnings per share.

Several other brokerages have also recently commented on XENE. HC Wainwright restated a “buy” rating and set a $53.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, May 13th. William Blair reissued an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Monday, May 5th. Chardan Capital reaffirmed a “buy” rating and set a $55.00 price objective on shares of Xenon Pharmaceuticals in a report on Tuesday, May 13th. The Goldman Sachs Group dropped their target price on Xenon Pharmaceuticals from $60.00 to $52.00 and set a “buy” rating for the company in a research report on Thursday, April 17th. Finally, Wells Fargo & Company decreased their price target on Xenon Pharmaceuticals from $50.00 to $47.00 and set an “overweight” rating on the stock in a report on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $54.82.

Xenon Pharmaceuticals Trading Up 0.3%

NASDAQ:XENE opened at $32.26 on Tuesday. The stock has a market capitalization of $2.48 billion, a P/E ratio of -11.44 and a beta of 1.09. Xenon Pharmaceuticals has a 1 year low of $26.74 and a 1 year high of $46.00. The firm has a 50 day moving average of $32.81 and a 200-day moving average of $36.53.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several hedge funds have recently modified their holdings of XENE. GF Fund Management CO. LTD. raised its position in Xenon Pharmaceuticals by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 1,952 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 351 shares in the last quarter. Natixis Advisors LLC raised its stake in Xenon Pharmaceuticals by 1.9% in the first quarter. Natixis Advisors LLC now owns 24,010 shares of the biopharmaceutical company’s stock valued at $806,000 after buying an additional 456 shares during the period. Occudo Quantitative Strategies LP lifted its position in shares of Xenon Pharmaceuticals by 5.8% in the fourth quarter. Occudo Quantitative Strategies LP now owns 11,441 shares of the biopharmaceutical company’s stock valued at $448,000 after buying an additional 630 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Xenon Pharmaceuticals by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 69,529 shares of the biopharmaceutical company’s stock worth $2,726,000 after acquiring an additional 720 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Xenon Pharmaceuticals during the 1st quarter worth approximately $30,000. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.